Furthermore, 1,25(OH)2D3 treatment did not affect the expression of CD14, of the chemokine receptor CCR7, and of the inhibitory molecules PD-L1 and ILT-3 by mo-DC from both healthy controls and MS patients (Supplementary Figure  1). This evidence concerns the gene CD14 and myeloid sarcoma.